|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Abciximab#Pharmacology]] |
| {{drugbox-mab |
| |
| | image =
| |
| | source = chimeric/human
| |
| | target = CD41 7E3
| |
| | CAS_number = 143653-53-6
| |
| | ATC_prefix = B01
| |
| | ATC_suffix = AC13
| |
| | ATC_supplemental =
| |
| | PubChem =
| |
| | DrugBank = BTD00041
| |
| | C=6462 | H=9964 | N=1690 | O=2049 | S=48
| |
| | molecular_weight = 145651.1 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life = <10 min-30 min
| |
| | pregnancy_category = C <small>(US)</small>
| |
| | legal_status =
| |
| | routes_of_administration = [[Intravenous|IV]]
| |
| }}
| |
| {{CMG}}
| |
| | |
| {{Editor Join}}
| |
| | |
| {{SI}}
| |
| | |
| '''''Synonyms:''''' 7E3 antibody, ReoPro, abciximab, c7E3
| |
| | |
| | |
| ==[[Abciximab (patient information)|For patient information, click here]]==
| |
| | |
| ==[http://www.drugbank.ca/drugBank/drugStructureFile/drug_files/fda_labels/DB00054.pdf For FDA label click here]==
| |
| | |
| '''Abciximab''' (previously known as '''c7E3 Fab'''), manufactured by [[Centocor]] and distributed by [[Eli Lilly and Company|Eli Lilly]] under the trade name '''ReoPro'''<sup>®</sup>, is a platelet aggregation inhibitor mainly used during and after [[coronary artery]] procedures like [[angioplasty]] to prevent [[platelet]]s from sticking together and causing thrombus ([[blood clot]]) formation within the coronary artery. Its mechanism of action is inhibition of glycoprotein IIb/IIIa.
| |
| | |
| While Abciximab has a short plasma half life, due to its strong affinity for its receptor on the [[platelet]]s, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 24 to 48 hours after discontinuation of the drug.
| |
| | |
| Abciximab is made from the [[Fragment antigen binding|Fab]] fragments of an [[immunoglobulin]] that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
| |
| | |
| ==Indications for use==
| |
| Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure<ref>Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994 Apr 7;330(14):956-61. PMID 8121459.</ref> and a decreased need for repeated coronary artery revascularization in the first month following the procedure.<ref>Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25. PMID 12939213.</ref>
| |
| | |
| ==Contraindications==
| |
| Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:
| |
| * Active internal bleeding
| |
| * Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.
| |
| * History of cerebrovascular accident ([[CVA]]) within two years, or [[CVA]] with a significant residual neurological deficit
| |
| * Bleeding diathesis
| |
| * Administration of oral [[anticoagulant]]s within seven days unless [[prothrombin time]] is <1.2 times control
| |
| * [[Thrombocytopenia]] (<100 000 cells/m L)
| |
| * Recent (within six weeks) major surgery or [[trauma]]
| |
| * Intracranial neoplasm, [[arteriovenous malformation]], or [[aneurysm]]
| |
| * Severe uncontrolled [[hypertension]]
| |
| * Presumed or documented history of [[vasculitis]]
| |
| * Use of intravenous [[dextran]] before PCI, or intent to use it during an intervention
| |
| * Abciximab is also contraindicated in patients with known [[hypersensitivity]] to any component of this product or to murine proteins.
| |
| | |
| ==Pharmacokinetics==
| |
| Abciximab has a plasma [[half life]] of about ten minutes, with a second phase half life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated.
| |
| | |
| ==Drug Interactions==
| |
| Formal drug interaction studies with Abciximab have not been conducted. Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina, [[myocardial infarction]] and [[hypertension]]. These medications have included [[heparin]], [[beta-adrenergic receptor blocker]]s, [[calcium channel antagonist]]s, [[angiotensin converting enzyme inhibitor]]s, intravenous and oral [[nitrate]]s, [[ticlopidine]], and [[aspirin]]. Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding. Patients with [[HACA]] titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
| |
| | |
| ==Side effects==
| |
| Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal [[hemorrhage]]. If severe or intractable bleeding develops, the infusion of the drug should be discontinued. Platelets can be administered to partially reverse the effect of the drug. Given that the drug binds avidly to the platelets that it is already bound to, the drug will not bind to new platelets.
| |
| | |
| [[Thrombocytopenia]] is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of [[platelet]]s.
| |
| Abciximab induced thrombocytopenia can last for five days after initial drug administration. Transfusing platelets is the only known treatment and may have limited effectiveness as the drug may also bind to the new platelets.
| |
| | |
| ===Bleeding===
| |
| | |
| Abciximab has the potential to increase the risk of bleeding, particularly in the presence of anticoagulation, e.g., from [[heparin]], other [[anticoagulant]]s or [[thrombolytics]]. Bleeding in the Phase 3 trials was classified as major, minor or insignificant by the criteria of the Thrombolysis in Myocardial Infarction study group. Major bleeding events were defined as either an [[intracranial hemorrhage]] or a decrease in [[hemoglobin]] greater than 5 g/dL. Minor bleeding events included spontaneous gross [[hematuria]], spontaneous [[hematemesis]], observed blood loss with a hemoglobin decrease of more than 3 g/dL, or a decrease in hemoglobin of at least 4 g/dL without an identified bleeding site. Insignificant bleeding events were defined as a decrease in hemoglobin of less than 3 g/dL or a decrease in hemoglobin between 3-4 g/dL without observed bleeding. In patients who received transfusions, the number of units of blood lost was estimated through an adaptation of the method of Landefeld, et al.
| |
| | |
| In the EPIC trial, in which a non-weight-adjusted, longer-duration heparin dose regimen was used, the most common complication during Abciximab therapy was bleeding during the first 36 hours. The incidences of major bleeding, minor bleeding and transfusion of blood products were significantly increased. Major bleeding occurred in 10.6% of patients in the Abciximab bolus plus infusion arm compared with 3.3% of patients in the placebo arm. Minor bleeding was seen in 16.8% of Abciximab bolus plus infusion patients and 9.2% of placebo patients. Approximately 70% of Abciximab-treated patients with major bleeding had bleeding at the arterial access site in the groin. Abciximab-treated patients also had a higher incidence of major bleeding events from gastrointestinal, genitourinary, retroperitoneal, and other sites.
| |
| | |
| Bleeding rates were reduced in the CAPTURE trial, and further reduced in the EPILOG and EPISTENT trials by use of modified dosing regimens and specific patient management techniques. In EPILOG and EPISTENT, using the heparin and Abciximab dosing, sheath removal and arterial access site guidelines described under PRECAUTIONS, the incidence of major bleeding in patients treated with Abciximab and low-dose, weight-adjusted heparin was not significantly different from that in patients receiving placebo.
| |
| | |
| Subgroup analyses in the EPIC and CAPTURE trials showed that non-CABG major bleeding was more common in Abciximab patients weighing ≤ 75 kg. In the EPILOG and EPISTENT trials, which used weight-adjusted heparin dosing, the non-CABG major bleeding rates for Abciximab-treated patients did not differ substantially by weight subgroup.
| |
| | |
| Although data are limited, Abciximab treatment was not associated with excess major bleeding in patients who underwent CABG surgery. (The range among all treatment arms was 3-5% in EPIC, and 1-2% in the CAPTURE, EPILOG, and EPISTENT trials.) Some patients with prolonged bleeding times received platelet transfusions to correct the bleeding time prior to surgery. (see PRECAUTIONS: Restoration of Platelet Function.)
| |
| Pulmonary alveolar hemorrhage has been rarely reported during use of Abciximab. This can present with any or all of the following in close association with ReoPro administration: [[hypoxemia]], alveolar infiltrates on chest x-ray, [[hemoptysis]], or an unexplained drop in hemoglobin.
| |
| | |
| ===Intracranial Hemorrhage and Stroke===
| |
| | |
| The total incidence of intracranial hemorrhage and non-hemorrhagic stroke across all four trials was not significantly different, 9/3023 for placebo patients and 15/4680 for Abciximab-treated patients. The incidence of intracranial hemorrhage was 3/3023 for placebo patients and 7/4680 for Abciximab patients.
| |
| | |
| ===Thrombocytopenia===
| |
| | |
| In the clinical trials, patients treated with Abciximab were more likely than patients treated with placebo to experience decreases in platelet counts.
| |
| | |
| Among patients in the EPILOG and EPISTENT trials who were treated with Abciximab plus low-dose heparin, the proportion of patients with any thrombocytopenia (platelets less than 100,000 cells/µL) ranged from 2.5 to 3.0%. The incidence of severe thrombocytopenia (platelets less than 50,000 cells/µL) ranged from 0.4 to 1.0% and platelet transfusions were required in 0.9 to 1.1%, respectively. Modestly lower rates were observed among patients treated with placebo plus standard-dose heparin. Overall higher rates were observed among patients in the EPIC and CAPTURE trials treated with Abciximab plus longer duration heparin: 2.6 to 5.2% were found to have any thrombocytopenia, 0.9 to 1.7% had severe thrombocytopenia, and 2.1 to 5.5% required platelet transfusion, respectively.
| |
| | |
| In a readministration registry study of patients receiving a second or subsequent exposure to Abciximab (see PRECAUTIONS: Readministration) the incidence of any degree of throm-bocytopenia was 5%, with an incidence of profound thrombocytopenia of 2% ( < 20,000 cell/µL). Factors associated with an increased risk of thrombocytopenia were a history of thrombocytopenia on previous Abciximab exposure, readministration within 30 days, and a positive HACA assay prior to the readministration.
| |
| | |
| Among 14 patients who had thrombocytopenia associated with a prior exposure to Abciximab, 7(50%) had recurrent thrombocytopenia. In 130 patients with a readministration interval of 30 days or less, 25 (19%) developed thrombocytopenia. Severe thrombocytopenia occurred in 19 of these patients. Among the 71 patients who had a positive HACA assay at baseline, 11 (15%) developed thrombocytopenia, 7 of which were severe.
| |
| | |
| ===Allergic Reactions===
| |
| | |
| There have been rare reports of allergic reactions, some of which were anaphylaxis (see WARNINGS: Allergic Reactions).
| |
| | |
| ===Other Adverse Reactions===
| |
| | |
| The following additional adverse events from the EPIC, EPILOG and CAPTURE trials were reported by investigators for patients treated with a bolus plus infusion of Abciximab at incidences which were less than 0.5% higher than for patients in the placebo arm.
| |
| | |
| Cardiovascular System: ventricular tachycardia (1.4%), pseudoaneurysm (0.8%), palpitation (0.5%), arteriovenous fistula (0.4%), incomplete AV block (0.3%), nodal arrhythmia (0.2%), complete AV block (0.1%), embolism (limb)(0.1%); thrombophlebitis (0.1%);
| |
| | |
| Gastrointestinal System: dyspepsia (2.1%), diarrhea (1.1%), ileus (0.1%), gastroesophogeal reflux (0.1%); Hemic and Lymphatic System: anemia (1.3%), leukocytosis (0.5%), petechiae (0.2%);
| |
| | |
| Nervous System: dizziness (2.9%), anxiety (1.7%), abnormal thinking (1.3%), agitation (0.7%), hypesthesia (0.6%), confusion (0.5%) muscle contractions (0.4%), coma (0.2%), hypertonia (0.2%), diplopia (0.1%);
| |
| | |
| Respiratory System: pneumonia (0.4%), rales (0.4%), pleural effusion (0.3%), bronchitis (0.3%), bronchospasm (0.3%), pleurisy (0.2%), pulmonary embolism (0.2%), rhonchi (0.1%);
| |
| | |
| Musculoskeletal System: myalgia (0.2%);
| |
| | |
| Urogenital System: urinary retention (0.7%), dysuria (0.4%), abnormal renal function (0.4%), frequent micturition (0.1%), cystalgia (0.1%), urinary incontinence (0.1%), prostatitis (0.1%);
| |
| | |
| Miscellaneous: pain (5.4%), sweating increased (1.0%), asthenia (0.7%), incisional pain (0.6%), pruritus (0.5%), abnormal vision (0.3%), edema (0.3%), wound (0.2%), abscess (0.2%), cellulitis (0.2%), peripheral coldness (0.2%), injection site pain (0.1%), dry mouth (0.1%), pallor (0.1%), diabetes mellitus (0.1%), hyperkalemia (0.1%), enlarged abdomen (0.1%), bullous eruption (0.1%), inflammation (0.1%), drug toxicity (0.1%).
| |
| | |
| ===Immunogenicity===
| |
| | |
| As with all therapeutic proteins, there is a potential for immunogenicity. In the EPIC, EPILOG, and CAPTURE trials, positive HACA responses occurred in approximately 5.8% of these patients receiving a first exposure to Abciximab. No increase in hypersensitivity or allergic reactions was observed with Abciximab treatment (see WARNINGS: Allergic Reactions).
| |
| | |
| In a study of readministration of Abciximab to patients (see PRECAUTIONS: Readministration) the overall rate of HACA positivity prior to the readministration was 6% and increased post-readministration to 27%. Among the 36 subjects receiving a fourth or greater Abciximab exposure, HACA positive assays were observed post-readministration in 16 subjects (44%). There were no reports of serious allergic reactions or anaphylaxis (see WARNINGS: Allergic Reactions). HACA positive status was associated with an increased risk of throm-bocytopenia (see PRECAUTIONS: Thrombocytopenia).
| |
| | |
| The data reflect the percentage of patients whose test results were considered positive for antibodies to Abciximab using an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Abciximab with the incidence of antibodies to other products may be misleading.
| |
| | |
| ==PRECAUTIONS==
| |
| ===Bleeding Precautions===
| |
| | |
| To minimize the risk of bleeding with Abciximab, it is important to use a low-dose, weight-adjusted heparin regimen, a weight-adjusted Abciximab bolus and infusion, strict anticoagulation guidelines, careful vascular access site management, discontinuation of heparin after the procedure and early femoral arterial sheath removal.
| |
| | |
| Therapy with Abciximab requires careful attention to all potential bleeding sites including catheter insertion sites, arterial and venous puncture sites, cutdown sites, needle puncture sites, and gastrointestinal, genitourinary, pulmonary (alveolar), and retroperitoneal sites.
| |
| | |
| Arterial and venous punctures, intramuscular injections, and use of urinary catheters, nasotracheal intubation, nasogastric tubes and automatic blood pressure cuffs should be minimized. When obtaining intravenous access, non-compressible sites (e.g., subclavian or jugular veins) should be avoided. Saline or heparin locks should be considered for blood drawing. Vascular puncture sites should be documented and monitored. Gentle care should be provided when removing dressings.
| |
| | |
| Femoral artery access site—Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bed rest with the head of the bed ≤ 30° and the affected limb restrained in a straight position. Patients may be medicated for back/groin pain as necessary.
| |
| | |
| Discontinuation of heparin immediately upon completion of the procedure and removal of the arterial sheath within six hours is strongly recommended if APTT ≤ 50 sec or ACT ≤ 175 sec (see PRECAUTIONS: Laboratory Tests). In all circumstances, heparin should be discontinued at least two hours prior to arterial sheath removal.
| |
| | |
| Following sheath removal, pressure should be applied to the femoral artery for at least 30 minutes using either manual compression or a mechanical device for hemostasis. A pressure dressing should be applied following hemostasis. The patient should be maintained on bed rest for six to eight hours following sheath removal or discontinuation of Abciximab, or four hours following discontinuation of heparin, whichever is later. The pressure dressing should be removed prior to ambulation. The sheath insertion site and distal pulses of affected leg(s) should be frequently checked while the femoral artery sheath is in place and for six hours after femoral artery sheath removal. Any hematoma should be measured and monitored for enlargement.
| |
| | |
| The following conditions have been associated with an increased risk of bleeding and may be additive with the effect of Abciximab in the angioplasty setting: PCI within 12 hours of the onset of symptoms for acute myocardial infarction, prolonged PCI (lasting more than 70 minutes) and failed PCI.
| |
| Use of Thrombolytics, Anticoagulants and Other Antiplatelet Agents
| |
| | |
| In the EPIC, EPILOG, CAPTURE, and EPISTENT trials, Abciximab was used concomitantly with heparin and aspirin. For details of the anticoagulation algorithms used in these clinical trials, see Clinical Studies: Anticoagulation. Because Abciximab inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including thrombolytics, oral anticoagulants, non-steroidal anti-inflammatory drugs, dipyridamole, and ticlopidine.
| |
| | |
| In the EPIC trial, there was limited experience with the administration of Abciximab with low molecular weight dextran. Low molecular weight dextran was usually given for the deployment of a coronary stent, for which oral anticoagulants were also given. In the 11 patients who received low molecular weight dextran with Abciximab, five had major bleeding events and four had minor bleeding events. None of the five placebo patients treated with low molecular weight dextran had a major or minor bleeding event (see CONTRAINDICATIONS).
| |
| | |
| Because of observed synergistic effects on bleeding, Abciximab therapy should be used judiciously in patients who have received systemic thrombolytic therapy. The GUSTO V trial randomized patients with acute myocardial infarction to treatment with combined Abciximab and half-dose Reteplase, or full-dose Reteplase alone (15). In this trial, the incidence of moderate or severe nonintracranial bleeding was increased in those patients receiving Abciximab and half-dose Reteplase versus those receiving Reteplase alone (4.6% versus 2.3%, respectively).
| |
| | |
| ===Thrombocytopenia===
| |
| | |
| Thrombocytopenia, including severe thrombocytopenia, has been observed with Abciximab administration (see ADVERSE REACTIONS: Thrombocytopenia). Platelet counts should be monitored prior to, during, and after treatment with Abciximab. Acute decreases in platelet count should be differentiated between true thrombocytopenia and pseudothrombocytopenia (see PRECAUTIONS: Laboratory Tests). If true thrombocytopenia is verified, Abciximab should be immediately discontinued and the condition appropriately monitored and treated.
| |
| | |
| In clinical trials, patients who developed thrombocytopenia were followed with daily platelet counts until their platelet count returned to normal. Heparin and aspirin were discontinued for platelet counts below 60,000 cells/µL and platelets were transfused for a platelet count below 50,000 cells/µL. Most cases of severe thrombocytopenia ( < 50,000 cells/µL) occurred within the first 24 hours of Abciximab administration.
| |
| | |
| In a registry study of Abciximab readministration, a history of thrombocytopenia associated with prior use of Abciximab was predictive of an increased risk of recurrent thrombocytopenia (see ADVERSE REACTIONS: Thrombocytopenia). Readministration within 30 days was associated with an increased incidence and severity of thrombocytopenia, as was a positive human anti-chimeric antibody (HACA) test at baseline, compared to the rates seen in studies with first administration.
| |
| Restoration of Platelet Function
| |
| | |
| In the event of serious uncontrolled bleeding or the need for emergency surgery, Abciximab should be discontinued. If platelet function does not return to normal, it may be restored, at least in part, with platelet transfusions.
| |
| Laboratory Tests
| |
| | |
| Before infusion of Abciximab, prothrombin time, ACT, APTT, and platelet count should be measured to identify pre-existing hemostatic abnormalities.
| |
| | |
| Based on an integrated analysis of data from all studies, the following guidelines may be utilized to minimize the risk for bleeding:
| |
| | |
| When Abciximab is initiated 18 to 24 hours before PCI, the APTT should be maintained between 60 and 85 seconds during the Abciximab and heparin infusion period.
| |
| | |
| During PCI the ACT should be maintained between 200 and 300 seconds.
| |
| | |
| If anticoagulation is continued in these patients following PCI, the APTT should be maintained between 55 and 75 seconds.
| |
| | |
| The APTT or ACT should be checked prior to arterial sheath removal. The sheath should not be removed unless APTT ≤ 50 seconds or ACT ≤ 175 seconds.
| |
| | |
| Platelet counts should be monitored prior to treatment, two to four hours following the bolus dose of Abciximab and at 24 hours or prior to discharge, whichever is first. If a patient experiences an acute platelet decrease (e.g., a platelet decrease to less than 100,000 cells/µL and a decrease of at least 25% from pre-treatment value), additional platelet counts should be determined. Platelet monitoring should continue until platelet counts return to normal.
| |
| | |
| To exclude pseudothrombocytopenia, a laboratory artifact due to in vitro anticoagulant interaction, blood samples should be drawn in three separate tubes containing ethylenedi-aminetetraacetic acid (EDTA), citrate and heparin, respectively. A low platelet count in EDTA but not in heparin and/or citrate is supportive of a diagnosis of pseudothrombocytopenia.
| |
| | |
| ===Readministration===
| |
| | |
| Administration of Abciximab may result in the formation of HACA that could potentially cause allergic or hypersensitivity reactions (including anaphylaxis), thrombocytopenia or diminished benefit upon readministration of Abciximab (see WARNINGS: Allergic Reactions; see ADVERSE REACTIONS: Immunogenicity).
| |
| | |
| Readministration of Abciximab to patients undergoing PCI was assessed in a registry that included 1342 treatments in 1286 patients. Most patients were receiving their second Abciximab exposure; 15% were receiving the third or subsequent exposure. The overall rate of HACA positivity prior to the readministration was 6% and increased to 27% post-readministration. There were no reports of serious allergic reactions or anaphylaxis (see WARNINGS: Allergic Reactions). Thrombocytopenia was observed at higher rates in the readministration study than in the phase 3 studies of first-time administration (see PRECAUTIONS: Thrombocytopenia and ADVERSE REACTIONS: Thrombocytopenia), suggesting that readministration may be associated with an increased incidence and severity of thrombocytopenia.
| |
| Carcinogenesis, Mutagenesis and Impairment of Fertility
| |
| | |
| In vitro and in vivo mutagenicity studies have not demonstrated any mutagenic effect. Long-term studies in animals have not been performed to evaluate the carcinogenic potential or effects on fertility in male or female animals.
| |
| | |
| ===Pregnancy Category C===
| |
| | |
| Animal reproduction studies have not been conducted with Abciximab. It is also not known whether Abciximab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Abciximab should be given to a pregnant woman only if clearly needed.
| |
| Nursing Mothers
| |
| | |
| It is not known whether this drug is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, caution should be exercised when Abciximab is administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been studied.
| |
| | |
| ===Geriatric Use===
| |
| | |
| Of the total number of 7860 patients in the four Phase 3 trials, 2933 (37%) were 65 and over, while 653 (8%) were 75 and over. No overall differences in safety or efficacy were observed between patients of age 65 to less than 75 as compared to younger patients. The clinical experience is not adequate to determine whether patients of age 75 or greater respond differently than younger patients.
| |
| | |
| ==Dosing and Administration==
| |
| The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.
| |
| | |
| Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCI.
| |
| | |
| Instructions for Administration
| |
| | |
| #Parenteral drug products should be inspected visually for particulate matter prior to administration. Preparations of Abciximab containing visibly opaque particles should NOT be used.
| |
| #[[Hypersensitivity reaction]]s should be anticipated whenever protein solutions such as Abciximab are administered. [[Epinephrine]], [[dopamine]], [[theophylline]], [[antihistamines]] and [[corticosteroid]]s should be available for immediate use. If symptoms of an allergic reaction or [[anaphylaxis]] appear, the infusion should be stopped and appropriate treatment given (see WARNINGS: Allergic Reactions). | |
| #As with all parenteral drug products, aseptic procedures should be used during the administration of Abciximab. | |
| #Withdraw the necessary amount of Abciximab for bolus injection into a syringe. Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 µm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent).
| |
| #Withdraw the necessary amount of Abciximab for the continuous infusion into a syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and infuse at the calculated rate via a continuous infusion pump. The continuous infusion should be filtered either upon admixture using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 µm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 µm filter (Abbott #4524 or equivalent). Discard the unused portion at the end of the infusion.
| |
| #No incompatibilities have been shown with intravenous infusion fluids or commonly used cardiovascular drugs. Nevertheless, Abciximab should be administered in a separate intravenous line whenever possible and not mixed with other medications.
| |
| #No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets.
| |
| | |
| ==How Supplied==
| |
| Abciximab (ReoPro) 2 mg/mL is supplied in 5 mL vials containing 10 mg (NDC 0002-7140-01).
| |
| | |
| Vials should be stored at 2 to 8 8°C (36 to 46 8°F). Do not freeze. Do not shake. Do not use beyond the expiration date. Discard any unused portion left in the vial.
| |
| | |
| ==References==
| |
| <references/>
| |
| | |
| ==External links==
| |
| * [http://www.abciximab.com Official website]
| |
| | |
| | |
| {{Antithrombotics}}
| |
| {{Chimericmonoclonals}}
| |
| | |
| [[Category:gpIIb/IIIa inhibitors]]
| |
| [[Category:Monoclonal antibodies]]
| |
| [[Category:Centocor]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| | |
| [[es:Abciximab]]
| |
| [[pt:Abciximab]]
| |